Targeted therapies for rare lung diseases


Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, now in a Phase 2b study, is an inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.


Avalyn is developing inhaled formulations of approved medications to treat rare respiratory diseases. Our initial focus is on the treatment of Interstitial Lung Diseases, including Pulmonary Fibrosis, and rare diseases that have dramatic impacts on patient quality of life.


May 28, 2024

Avalyn to Participate in Jefferies Global Healthcare Conference
Read more »

May 20, 2024

Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024
Read more »

May 13, 2024

Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference
Read more »

May 1, 2024

Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
Read more »